EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Population Pharmacokinetics of Rifampicin in Plasma and Cerebrospinal Fluid in Adults With Tuberculosis Meningitis

Noha Abdelgawad iD, Sean Wasserman iD, Kamunkhwala Gausi iD, Angharad Davis iD, Cari Stek iD, Lubbe Wiesner iD, Graeme Meintjes iD, Robert J Wilkinson iD, Paolo Denti iD

The Journal of Infectious Diseases · 29.04.2025

DOI: 10.1093/infdis/jiaf178 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 29.04.2025. Verfasst von Noha Abdelgawad und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine. Hauptthemen laut MEDLINE: Antibiotics, Antitubercular, Antitubercular Agents, Rifampin, Tuberculosis, Meningeal. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Bill & Melinda Gates Foundation, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Several ongoing clinical trials are evaluating high-dose rifampicin (up to 35 mg/kg) for tuberculous meningitis (TBM). However, rifampicin pharmacokinetics at higher doses is not fully characterized, particularly in cerebrospinal fluid (CSF), the site of TBM disease.

Methods

In a randomized controlled trial, adults with HIV-associated TBM were assigned to experimental arms of high-dose rifampicin (oral, 35 mg/kg; intravenous, 20 mg/kg) plus linezolid, with or without aspirin, or a control arm that received the standard of care with 10 mg/kg of oral rifampicin. Rifampicin concentrations, including the unbound fraction, were measured on plasma samples, and CSF was collected on days 3 and 28 of study enrollment. Data were analyzed by nonlinear mixed effects modeling.

Results

In total, 400 plasma and 44 CSF rifampicin concentrations from 48 participants were used for model development. The median (range) age and weight were 39 years (25–78) and 60 kg (30–107). Rifampicin pharmacokinetics was best described by a 2-compartment disposition model with first-order transit oral absorption and elimination via saturable hepatic extraction. Typical clearance values for the standard dose for days 3 and 28 were 33.1 and 41.4 L/h, respectively; high-dose values were 46.1 and 70.2 L/h. The CSF-plasma ratio was approximately 6% and the equilibration half-life was 3.2 hours. Simulated standard-dose rifampicin did not reach CSF concentrations above the critical concentration for Mycobacterium tuberculosis.

Conclusions

CSF penetration with standard-dose rifampicin is low. Our findings support continued evaluation of high-dose rifampicin for TBM treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibiotics, AntitubercularAntitubercular AgentsRifampinTuberculosis, MeningealAdultAgedFemaleHumansMaleMiddle AgedAdministration, OralHIV InfectionsLinezolidPlasma

Stichwörter der Autor:innen

cerebrospinal fluidhigh-dose rifampicinmodeling and simulationpopulation pharmacokineticstuberculosis meningitis

Substanzen

Antibiotics, AntitubercularAntitubercular AgentsLinezolidRifampin

Autor:innen und Institutionen

  • Division of Clinical Pharmacology, Department of Medicine.
  • Wellcome Discovery Research Platforms for Infection, Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa.
  • Institute for Infection and Immunity, City St George's University of London, London, United Kingdom.
  • The Francis Crick Institute, London, United Kingdom.
  • Queen Mary and Barts Tuberculosis Centre, Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University London, United Kingdom.
  • Department of Medicine, University of Cape Town, Observatory, South Africa.

ORCID-Profile: Noha Abdelgawad, Sean Wasserman, Kamunkhwala Gausi, Angharad Davis, Cari Stek, Lubbe Wiesner, Graeme Meintjes, Robert J Wilkinson, Paolo Denti

Förderung

  • Wellcome Trust
  • Bill & Melinda Gates Foundation
  • NIAID NIH HHS
  • NIH HHS
  • NIMH NIH HHS
  • UCL Wellcome Trust
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Abdelgawad, N., Wasserman, S., Gausi, K., Davis, A., Stek, C., Wiesner, L., Meintjes, G., Wilkinson, R. J., & Denti, P. (2025). Population Pharmacokinetics of Rifampicin in Plasma and Cerebrospinal Fluid in Adults With Tuberculosis Meningitis. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf178

Vancouver

Abdelgawad N, Wasserman S, Gausi K, Davis A, Stek C, Wiesner L, et al. Population Pharmacokinetics of Rifampicin in Plasma and Cerebrospinal Fluid in Adults With Tuberculosis Meningitis. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf178

BibTeX
@article{Abdelgawad2025,
  author = {Abdelgawad, Noha and Wasserman, Sean and Gausi, Kamunkhwala and Davis, Angharad and Stek, Cari and Wiesner, Lubbe and Meintjes, Graeme and Wilkinson, Robert J and Denti, Paolo},
  title = {Population Pharmacokinetics of Rifampicin in Plasma and Cerebrospinal Fluid in Adults With Tuberculosis Meningitis},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiaf178}
}
Kostenlos starten →